

Alcohol Consumption in Heroin Users, Methadone-Substituted and Codeine-Substituted Patients – Frequency and Correlates of Use

Markus Backmund^a Christian G. Schütz^b Kirsten Meyer^a
Dieter Eichenlaub^a Michael Soyka^b

^aAddiction Medicine, General Hospital Munich-Schwabing, and ^bDepartment of Psychiatry, University of Munich, Germany

Key Words

Co-abuse · Alcohol · Methadone · Dihydrocodeine · Heroin

Abstract

This retrospective study aims to determine whether there is a difference in the additional consumption of alcohol between addicts treated with methadone or dihydrocodeine (DHC) and untreated addicts injecting heroin. 1,685 patients admitted for opioid withdrawal between 1991 and 1997 were reviewed. Cross-reference tables and multiple logistic regression analyses were carried out. 28% of patients take more than 40 g of alcohol daily (on average 176 g). We found that patients who are treated with methadone or DHC drink alcohol significantly more often daily than the heroin-dependent patients ($p < 0.01$). Using multiple regression analyses, the results were confirmed. Additionally, we found that co-abuse of alcohol was predicted by male gender, longer duration of drug use, additional daily consumption of tetrahydrocannabinol and daily consumption of benzodiazepines. Alcohol consumption by opioid-addicted patients treated with methadone or DHC presents a serious medical problem. Co-abuse of alcohol will receive more attention.

Introduction

Consumption of other psychotropic substances during substitution treatment of opioid addicts with methadone and dihydrocodeine (DHC) may have a substantial impact on morbidity, mortality and clinical course. While consumption of illegal drugs is usually reduced during substitution treatment, additional consumption of legal psychotropic substances, especially of alcohol, has not been examined in such detail. Chronic alcohol consumption leads to a variety of somatic effects and diseases. Therefore, where a high prevalence of regular or severe alcohol consumption exists among patients in substitution programs, the advantages and risks should be carefully weighed up. Further, to the consumption of respiration-depressive opioids, additional complications and dangers are involved when taking other psychotropic substances with respiration-depressive effects, such as alcohol, benzodiazepines or barbiturates. 62–72% of the patients, who had been treated for overdosing, had consumed various substances [1, 2], of which 23–35% comprised alcohol. In cases of fatal overdosing, abuse with multiple substances was reported in 71–92% of patients [3–7]. In 41–51% of these deaths, alcohol was identified. In addition to the acute risk of an overdose from combined consumption of a number of psychotropic substances, the consumption of

Copyright © 2003 S. Karger AG, Basel

KARGER

Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com

© 2003 S. Karger AG, Basel
1022-6877/03/0091-0045\$19.50/0

Accessible online at:
www.karger.com/ear

Markus Backmund, MD
Krankenhaus München-Schwabing
Kölner Platz 1
D-80804 München (Germany)
Tel. +49 89 30683366, Fax +49 89 30683934, E-Mail Markus.Backmund@kms.mhn.de

alcohol, in contrast to opioids, leads to chronic permanent damage and disease concerning almost all aspects of medicine [8–11].

On the one hand, a number of studies have ascertained that the supplementary consumption of illegal drugs such as heroin and cocaine may be reduced by methadone maintenance treatment programs [12–15] and codeine maintenance programs [16]. On the other hand, it has often been reported that about 30% of the patients in methadone maintenance treatment programs have an alcohol problem or are even alcoholics [17–19]. It is not clear, however, whether the patients already had alcohol problems before their entry into the methadone maintenance treatment. The North Rhine Westphalia study on the efficacy of outpatient medical rehabilitation with methadone maintenance indicated that over time the number of patients being abstinent of alcohol increased during treatment [20].

In Germany, the critical dose is often stated as 60 g for men and 40 g for women [21]. More than 8,000 deaths of people aged 15–29 years in Europe in 1999 were attributable to alcohol [22].

In addition to the risk of overdosing, alcoholism for example leads to an increased risk of long-term secondary physical sicknesses [8, 9]. With regard to narcotics fatalities, toxicological data from southern Bavaria – the same area as in our study – indicate that alcohol is a frequent covariant in drug-related deaths and in patients treated with codeine (27% each) and that it is less frequent in methadone patients (16%) [23].

Those studies concerned with supplementary consumption within methadone and codeine maintenance treatment programs have mainly focused on the supplementary consumption of illegal drugs. We further consider that in Germany, and especially Bavaria, where alcohol is everywhere easily available and where alcohol consumption is well established (e.g. the 'Oktoberfest'), heroin addicts consider alcohol consumption analogous to a 'normal' individual's regular consumption of alcohol, and more so when heroin becomes more difficult to obtain. We thus present our hypothesis that those patients treated with methadone or DHC drink less alcohol than the untreated patients injecting illegal heroin.

Subjects and Methods

Sample

All drug-addicted patients voluntarily admitted to inpatient detoxification treatment between April 1991 and December 1996, in whom, according to ICD-10 criteria, an opioid or multiple-substance

addiction had been diagnosed, were included in the study. Of all patients enrolled in the treatment program between April 1991 and December 1996, those subjects coming for a second or third detoxification visit within this time period had to be excluded, except for the first visit, otherwise the assumption of independent observations would have been violated. Patients could come in of their own volition, and previous contact with a counsellor or physician was not necessary. The treatment strategy called 'qualified detoxification' has been described elsewhere [24].

Measures

On the day of admission, the daily intake of psychotropic substances over the preceding 6 months was established. The patients were questioned individually regarding their intake of opioids, especially heroin, codeine/DHC and methadone (*D*, *L*-methadone, levomethadone), and of other psychotropic substances such as nicotine, benzodiazepines, barbiturates, cocaine, cannabis, amphetamines/amphetamine derivatives and alcohol. The alcohol intake was noted in grams of alcohol per day. 500 ml beer was calculated as 20 g alcohol, 500 ml cognac (40%) or vodka (40%) as 160 g alcohol [21]. The declarations were verified by an immunoassay urine test (Triage®) and a KIMS test (kinetic interaction of microparticles in a solution).

The patients were divided into 3 groups according to the preferred opioid of each individual. Those who daily received methadone or levomethadone (summarized as methadone) were included in group 1, those who took codeine or DHC daily (summarized as DHC) in group 2 and those daily consuming heroin in group 3. If primarily two opioids were taken daily, then the priority sequence of heroin before methadone before DHC was decisive. If none of the opioids were taken daily, but rather several of them alternatively, then these patients were not introduced into any of the 3 groups. Data concerning the daily intake of other psychotropic substances were collected for each group, as well as the gender of the patient, duration of addiction, age at first opioid use, age, marital status, history of imprisonment, history of suicide attempts and employment. Alcohol was separated and selected as a dependent variable (co-abuse of alcohol). Co-abuse of alcohol was defined as consumption of more than 40 g alcohol per day. The 40-gram value was chosen since it is the stated critical dose of alcohol per day in most other published reports [21, 22, 25, 26].

Statistics

After cross-tabulation and bivariate analysis, a logistic regression model was established. Bivariate analyses were performed for the variable of interest and all further potentially relevant variables. Since preliminary analysis indicated nonlinear associations involving type of opioid dependency, age, duration of drug use, age at first opioid use, marital status and history of imprisonment, these variables were transformed from ordinal to categorical variables. Results are summarized by reporting a 'full model' that includes all investigated variables regardless of their statistical significance. Tests for interactions were used as a check on the uniformity assumption under which multiple regression estimates are derived.

Results

During the observation period from April 1991 to December 1996, 1,656 patients were voluntarily admitted to stationary qualified withdrawal treatment, 36% women and 64% men. 537 of these were patients readmitted within the given time frame. Of these patients only the first admission was included in the study in order not to violate the assumption of independent observations. 49 patients were not included since they had daily consumed several different opioids. 137 patients, 36% women and 64% men, who daily received methadone, were included in group 1. 658 patients, 34% women and 66% men, due to their daily intake of codeine/DHC were placed into group 2. 275 patients, 39% women and 61% men, daily consuming heroin formed group 3. The average age was 30.7 years in group 1, 28.9 years in group 2 and 28.3 years in group 3. The average duration of addiction to opioids was substantiated as 10.5 years in group 1, 8.9 years in group 2 and 8.2 years in group 3.

301 patients consumed more than 40 g alcohol per day. These were evaluated as positive for the dependent variable 'co-abuse of alcohol'. On average, alcohol consumption was 176 g/day (table 1).

Contrary to our hypothesis, the bivariate analysis indicated that patients who are in a methadone or DHC maintenance treatment program daily drink alcohol significantly more often than the heroin-dependent patients ($p < 0.01$). Fewer patients who were treated with DHC (31.3%) drink alcohol than patients who were treated with methadone (36.5%). Table 2 presents bivariate analyses on the key variable and possible confounding variables predicting co-abuse of alcohol. As shown, co-abuse of alcohol was predicted by male gender, older age, longer duration of drug use, additional daily consumption of tetrahydrocannabinol (THC), daily consumption of barbiturates and daily consumption of benzodiazepines.

Table 3 shows the results of a multiple logistic regression analysis. The key finding that patients consuming heroin drink less alcohol than patients who were treated with DHC or methadone persists even when all investigated variables regardless of their statistical significance were included in the model. Age and daily consumption of barbiturates turned out not to be a significant predictor of co-abuse of alcohol. None of the other previously entered significant variables like gender (odds ratio, OR, 0.61, 95% confidence interval, CI, 0.44–0.84, $p < 0.01$), duration of drug use (OR 0.19, 95% CI 0.05–0.74, $p < 0.05$), daily consumption of benzodiazepines (OR 0.52, 95% CI 0.38–0.71, $p < 0.001$) and daily consumption of

Table 1. Consumption of alcohol by opioid patients consuming more than 40 g of alcohol per day (defining 'co-abuse of alcohol')

Quantity of alcohol g/day	Patients (n = 301) %
40–60	12.0
61–120	23.9
121–180	27.2
181–240	13.3
More than 240	23.6
Total	100

THC (OR 0.67, 95% CI 0.47–0.95, $p < 0.05$) became insignificant, even though our variable of interest 'type of opioid dependency' remained only marginally significant (OR 2.38, 95% CI 1.42–4.00, $p < 0.001$; table 3).

Discussion

The aim of this study was to investigate the association between the consumption of alcohol and the daily preferred opioid (methadone, DHC or heroin). The results indicate that patients consuming heroin drink less alcohol on a regular basis. In comparison to the patients who consume DHC, patients in a methadone maintenance program drink alcohol more often (36.5% of the methadone patients vs. 31.3% of the DHC patients). The hypothesis had therefore to be rejected. One explanation might be due to the effect of the substance, i.e. that heroin is the one substance with which the desired effect according to the addicts may best be attained. Other opioids such as methadone and DHC do not completely produce the desired effect so that other additional substances, e.g. alcohol, are consumed. In published reports, problematic alcohol consumption by opiate users is given as varying between 12% [27], 32% [18, 28] and 42% [27]. In this spectrum, the individual subgroups of our study are found, with 16% problem drinkers in the heroin group, 31.3% in the codeine group and 36.5% in the methadone group. It is becoming increasingly possible in Europe to use various opioids as substitutes. This is understandable when one considers the high mortality rate of drug addicts, which, in a meta-analysis, was found to be more than 13 times greater than in the average populations' equivalent age group [29]. Researchers and practitioners are therefore required to re-evaluate indication positions and to annotate advantages and disadvantages of each substance. An

Table 2. Cross-tabulation and bivariate analyses for the primary variables of interest and secondary potentially relevant variables

Variable	Co-abuse of alcohol (more than 40 g alcohol per day)				
	n	%	OR	95% CI	p
Type of opioid dependency					0.0000
Methadone	137	36.5	3.02	1.88–4.85	0.0000
DHC	658	31.3	2.39	1.67–3.44	0.0000
Heroin	275	16.0	1		
Sex					
Female	377	21.2	0.58	0.43–0.78	0.0003
Male	693	31.7	1		
Age					0.0081
<23 years	217	21.7	0.58	0.37–0.91	0.0169
24–28 years	340	24.7	0.69	0.46–1.02	0.0639
29–34 years	324	33.0	1.04	0.70–1.52	0.0851
>34 years	186	32.3	1		
Duration of opioid use					0.0000
<1 year	79	06.3	0.14	0.64–1.96	0.0001
2–5 years	392	24.0	0.66	0.62–1.28	0.0316
6–10 years	251	30.3	0.90	0.66–1.47	0.6277
11–15 years	160	40.0	1.39	0.68–1.65	0.1438
>15 years	188	32.4	1		
Daily consumption of THC					
No	873	26.3	0.65	0.47–0.90	0.0100
Yes	197	35.5	1		
Daily consumption of barbiturates					
No	995	27.2	0.59	0.37–0.97	0.0352
Yes	75	38.7	1		
Daily consumption of benzodiazepines					
No	597	20.9	0.45	0.34–0.59	0.0000
Yes	473	37.0	1		

The variables 'age at first opioid use', 'marital status', 'history of imprisonment', 'history of emergency treatment', 'history of suicide attempts', 'employment' and 'daily consumption of cocaine' were not significant.

OR = Odds ratio; 95% CI = 95% confidence interval; THC = tetrahydrocannabinol.

important target criterion should be the parallel consumption of further psychotropic substances, especially alcohol. It is known that alcohol has a toxic effect on all organic systems and that therefore chronic consumption of alcohol causes many severe illnesses. If the patients now begin to drink alcohol during the methadone or DHC substitution treatment, then a serious responsibility falls upon the physicians to recognize, and where necessary to prevent, the injurious alcohol consumption being caused perhaps partly by the substitution treatment itself. Further studies had to be conducted to prove the association between methadone or other substitutes and drinking alcohol, and to investigate how long patients can be treated with methadone before the risk of excessive alcohol consumption increases significantly. A previous study showed that 29% of the patients initially began to drink

during the course of methadone maintenance treatment programs and that they are younger in comparison to non-opioid-addicted alcoholics [30]. Numerous studies continue to substantiate that patients during substitution treatment with methadone consume fewer illegal drugs, that the risk of HIV infection is reduced and that drug-related crime rates fall [20, 31–33]. DHC, which is frequently prescribed in Germany, appears to improve the addicts' situation just as well as methadone [16]. In all these studies, the illicit drug co-abuse but not alcohol was a target criterion. In a new study, it was reported that only one third of the patients in methadone maintenance treatment abstained from alcohol at the intake and follow-up [34]. It is known that with a lower dosage of methadone, co-abuse is higher [35]. Apparently, patients who discover they are hepatitis C positive, reduce their alcohol con-

Table 3. Multiple logistic regression analyses: full model for the primary variables of interest and secondary potentially relevant variables

Variable	Co-abuse of alcohol (more than 40 g alcohol per day)		
	OR	95% CI	p
Type of opioid dependency			0.0038
Methadone	2.38	1.42–4.00	0.0010
DHC	1.67	1.12–2.49	0.0124
Heroin	1		
Sex			
Female	0.61	0.44–0.84	0.0025
Male	1		
Age			0.7734
<23 years	0.71	0.27–1.82	0.4715
24–28 years	0.72	0.35–1.48	0.3711
29–34 years	0.92	0.55–1.55	0.7521
>34 years	1		
Duration of opioid use			0.0220
<1 year	0.19	0.05–0.74	0.0167
2–5 years	0.81	0.35–1.88	0.6253
6–10 years	0.98	0.49–1.96	0.9484
11–15 years	1.36	0.76–2.46	0.3022
>15 years	1		
Daily consumption of benzodiazepines			
No	0.52	0.38–0.71	0.0000
Yes	1		
Daily consumption of barbiturates			
No	0.82	0.48–1.41	0.4773
Yes	1		
Daily consumption of THC			
No	0.67	0.47–0.95	0.0252
Yes	1		

The variables 'marital status', 'history of imprisonment', 'history of emergency treatment', 'history of suicide attempts', 'employment', 'age at first opioid use' and 'daily consumption of cocaine' remained insignificant.

OR = Odds ratio; 95% CI = 95% confidence interval.

sumption considerably [28]. In principle it should be taken into consideration that in Germany alcohol is culturally accepted. Possibly the results would be somewhat different in a more abstinence-oriented culture.

Independently of the preferred daily opioid the following variables were associated with co-abuse of alcohol: (1) in the total population, males more often have an alcohol problem than females [36–38] – so it was not surprising that male opioid addicts more often had drunk alcohol daily than female opioid addicts; (2) that older patients, consuming drugs over a longer period, drink more alcohol

seems realistic since the drug alone no longer appears to have the desired effect; (3) this would be an analogous explanation of the significantly higher benzodiazepine and cannabis consumption. Barbiturates are consumed (in total) in such small quantities that its use is difficult to assess with certainty. The subgroup of cocaine users is also so small that an assessment here appears to be of little practical value.

The multiple logistic regression analysis result proves that patients who have been treated with methadone or have taken DHC drink quite significantly more than patients who have injected heroin intravenously. To our knowledge this has not yet been described thus in any other literature. It is nevertheless necessary to consider that this concerns a retrospective study. Being male, additional consumption of benzodiazepines and THC was also confirmed as independent predictor for alcohol co-abuse. Increased age was not asserted as an independent predictor, but duration of drug use was. This may be explained by the fact that increased age implies a longer period of drug use, since drug addicts in this study on average first began injecting heroin at 20 years of age. In the first year of opioid consumption, it appeared that the opioid itself achieved the desired effect. Not quite every sixteenth patient drinks alcohol additionally. Already from the second year onward every fourth patient drinks alcohol daily. From the sixth to the tenth year, the proportion was 30%, from the eleventh to the fifteenth year 40%. The effect of the opioid itself no longer appears to be sufficient. With an opioid consumption of more than 15 years, slightly fewer patients drank alcohol daily (32.4%). This is comparable to a British study in which a 32% harmful daily alcohol consumption has been diagnosed, where the average duration of opioid dependence was 17 years and the average age was 39 [28].

The results of this study suggest that co-abuse of alcohol should receive more attention in further studies of the effectiveness of substitution treatment programs with various substitution drugs. Particularly, a comparison between heroin and methadone should prove very interesting. More longitudinal studies are still needed.

Acknowledgements

This study was supported by the 'Modellprogramm Kompakttherapie im Verbund der Drogenhilfe 1990–1995' from the Department of Health of the Federal Republic of Germany. The authors would like to thank the staff of the detoxification unit 'villa' for their help with data collection and entry.

References

- 1 Darke S, Ross J, Hall W: Overdose among heroin users in Sydney, Australia. I. Prevalence and correlates of non-fatal overdose. *Addiction* 1996;91:405–411.
- 2 Backmund M, Pfab R, Rupp P, Zilker T: Häufiger Notfall: Intoxikationen Suchtkranker durch Drogen und psychotrope Substanzen. *Notarzt* 1999;15:29–33.
- 3 Heckmann W, Püschel K, Schmoltdt A, Schneider V, Schulz-Schaeffer W, Soellner R, Zenker H, Zenker J: Drogennotfallstudie; in Bundesministerium für Gesundheit (ed): Drogennot- und -todesfälle. Baden-Baden, Nomos, 1993, pp 132–149.
- 4 Cook S, Moeschler O, Michaud K, Yersin B: Acute opiate overdose: Characteristics of 190 consecutive cases. *Addiction* 1998;93:1559–1565.
- 5 Perret G, Deglon J-J, Kreek MJ, Ho A, La Harpe R: Lethal methadone intoxications in Geneva, Switzerland, from 1994 to 1998. *Addiction* 2000;95:1647–1653.
- 6 Schmidt-Kittler A, von Meyer L: Drogenbedingte Todesfälle 1998. *Suchtmedizin* 2000;2:103–109.
- 7 Grass H, Sticht G: Drogentod nach Haftentlassung – Untersuchung am Beispiel der Grossstadt Köln. *Suchtmedizin* 2001;3:97–100.
- 8 Gutjahr E, Gmel G, Rehm J: Relation between average alcohol consumption and disease: An overview. *Eur Addict Res* 2001;7:117–127.
- 9 Schuckit MA: Alkohol und Alkoholismus; in Braunwald E, Isselbacher KJ, Petersdorf RG, Wilson JD, Martin JB, Fauci AS (eds): *Harrison's Principles of Internal Medicine*. New York, McGraw-Hill, 1989, vol 2, pp 2480–2487.
- 10 Single E, Robson L, Rehm J, Xie X: Morbidity and mortality attributable to alcohol, tobacco, and illicit drug use in Canada. *Am J Public Health* 1999;89:385–390.
- 11 Gutjahr E, Gmel G, Rehm J: The relation between average alcohol consumption and disease: An overview. *Eur Addict Res* 2001;7:117–121.
- 12 Strain EC, Stitzer ML, Liebson IA, Bigelow GE: Dose-response effects of methadone in the treatment of opioid dependence. *Ann Intern Med* 1993;119:23–27.
- 13 Goldstein A, Herrera J: Heroin addicts and methadone treatment in Albuquerque: A 22-year follow-up. *Drug Alcohol Depend* 1995;40:139–150.
- 14 Strain EC, Bigelow GE, Liebson IA, Stitzer ML: Moderate- vs. high-dose methadone in the treatment of opioid dependence: A randomized trial. *JAMA* 1999;281:1000–1005.
- 15 Borg L, Broe DM, Ho A, Kreek MJ: Cocaine abuse sharply reduced in an effective methadone maintenance program. *J Addict Dis* 1999;18:63–75.
- 16 Krausz M, Verthein U, Degkwitz P, Haasen C, Raschke P: Maintenance treatment of opiate addicts in Germany with medications containing codeine – Results of a follow-up study. *Addiction* 1998;93:1161–1167.
- 17 Hunt DE, Strug DL, Goldsmith DS, Lipton DS, Robertson K, Truitt L: Alcohol use and abuse: Heavy drinking among methadone clients. *Am J Drug Alcohol Abuse* 1986;12:147–164.
- 18 Stastny D, Potter M: Alcohol abuse by patients undergoing methadone treatment programs. *Br J Addict* 1991;86:307–310.
- 19 Helander A, von Wachenfeldt J, Hiltunen A, Beck O, Liljeberg P, Borg S: Comparison of urinary 5-hydroxytryptophol, breath ethanol, and self-report for detection of recent alcohol use during outpatient treatment: A study on methadone patients. *Drug Alcohol Depend* 1999;56:33–38.
- 20 Vogt M, Kufner H, Weiler D: Katamnestiche Ergebnisse zur ambulanten medizinischen Rehabilitation unter Methadon-Substitution. *Suchtmedizin* 2000;2:93–102.
- 21 Soyka M: *Die Alkoholkrankheit – Diagnose und Therapie*. London, Chapman & Hall, 1995.
- 22 Rehm J, Gmel G, Room R, Frick U: Average volume of alcohol consumption, drinking patterns and related burden of mortality in young people in established market economies of Europe. *Eur Addict Res* 2001;7:148–151.
- 23 Schmidt-Kittler H, von Meyer L: Drogenbedingte Todesfälle 1998. *Suchtmedizin* 2000;2:103–109.
- 24 Backmund M, Meyer K, Eichenlaub D, Schütz CG: Predictors for completing an inpatient detoxification program among intravenous heroin users, methadone substituted and codeine substituted patients. *Drug Alcohol Depend* 2001;64:173–180.
- 25 Tuyns AJ, Pequignot G: Greater risk of ascitic cirrhosis in females in relation to alcohol consumption. *Int J Epidemiol* 1984;13:53–57.
- 26 Sorensen TIA, Bentsen KD, Eghoje K, Orholm M, Hoby G, Christoffersen PC: Prospective evaluation of alcohol abuse and alcoholic liver injury in men as predictors of development of cirrhosis. *Lancet* 1984;ii:241–244.
- 27 Green J, Jaffe JH, Carlisi JA, Zaks A: Alcohol use in the opiate use cycle of the heroin addict. *Int J Addict* 1978;13:1021–1033.
- 28 McCusker M: Influence of hepatitis C status on alcohol consumption in opiate users in treatment. *Addiction* 2001;96:1007–1014.
- 29 Hulse GK, English DR, Milne E, Holman CDJ: The quantification of mortality resulting from the regular use of illicit opiates. *Addiction* 1999;94:221–229.
- 30 Gelb AM, Richman B, Anhand OP: Quantitative and temporal relationships of alcohol use in narcotic addicts and methadone maintenance patients undergoing alcohol detoxification. *Am J Drug Alcohol Abuse* 1978;5:191–198.
- 31 Dole VP, Nyswander ME: Medical treatment for diacetylmorphine (heroin) addiction. *JAMA* 1965;193:646–650.
- 32 Grönbladh L, Öhlund LS, Gunne LM: Mortality in heroin addiction impact of methadone treatment. *Acta Psychiatr Scand* 1990;82:223–227.
- 33 Metzger DS, Woody GE, McLellan AT, O'Brien CP, Druley P, Navaline H, DePhillips D, Stolley P, Abrutyn E: Human immunodeficiency virus seroconversion among intravenous drug users in and out of treatment: An 18-month prospective follow-up. *J Acquir Immune Defic Syndr* 1993;6:1049–1055.
- 34 Gossop M, Marsden J, Stewart D, Rolfe A: Patterns of drinking and drinking outcomes among drug misusers: 1-year follow-up results. *J Subst Abuse Treat* 2000;19:45–50.
- 35 Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE: A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. *N Engl J Med* 2000;343:1290–1297.
- 36 Myers JK, Weissmann MM, Tischler GL, Holzer CE, Leaf PJ, Orvaschel H, Anthony JC, Boyd JH, Burke JD, Kramer M, et al: Six-month prevalence of psychiatric disorders in three communities 1980 to 1982. *Arch Gen Psychiatry* 1984;41:959–967.
- 37 Regier DA, Boyd JH, Burke JD, Rae DS, Myers JK, Kramer M, Robins LN, Lin KG, Karno M, Locke BZ: One-month prevalence of mental disorders in the United States. *Arch Gen Psychiatry* 1988;45:977–986.
- 38 Fichter M: *Verlauf psychischer Erkrankungen in der Bevölkerung*. Berlin, Springer, 1990.